– Additional CALLIPER MRI Analyses Show Reductions for Vidofludimus Calcium in Acute and Chronic Inflammatory Disease Activity –
– Completed Enrollment for Both Phase 3 ENSURE Trials of Vidofludimus Calcium in Relapsing Multiple Sclerosis; Top-Line Data Expected by End of 2026 –
NEW YORK , Nov. 26, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic and...
– Key Data Highlighting Vidofludimus Calcium's Therapeutic Potential in Multiple Sclerosis Presented at 41 st Congress of ECTRIMS  –
NEW YORK , Oct. 29, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...
NEW YORK , Oct. 1, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies...
– Vidofludimus Calcium Demonstrated Statistically Significant 24-Week Confirmed Disability Improvement in Phase 2 CALLIPER Trial in Progressive Multiple Sclerosis, With Over Two-Fold Probability Over...
– Fifth U.S. Patent Directed to Use of Vidofludimus Calcium in Multiple Sclerosis –
NEW YORK , Sept. 4, 2025 /PRNewswire/ -- Immunic, Inc.  (Nasdaq: IMUX) , a biotechnology company developing a clinical pipeline of orally administered, small molecule...